Oral Hsp90 Inhibitor IPI-493

An orally bioavailable formulation of the ansamycin derivative 17-amino-17-demethoxygeldanamycin (17-AG) with potential antineoplastic activity. Oral Hsp90 inhibitor IPI-493 binds to and inhibits Hsp90, which may result the in growth inhibition in sensitive tumor cell populations. Hsp90, a 90 kDa molecular chaperone, may be highly expressed in tumor cells, playing a key role in the conformational maturation, stability and function of other substrate or "client" proteins within the cell; many of these client proteins are involved in signal transduction, cell cycle regulation and apoptosis, and may include kinases, transcription factors and hormone receptors. (NCI Thesaurus)

YOU MAY ALSO LIKE

Oral Hemorrhage

Bleeding originating from the mouth.

Oral Health Impact Profile

Measures a person's perceptions of the social impact of oral disorders on their well-being; measures self-reported dysfunction, discomfort and disability attributed to…

Oral Gel Dosage Form

A gel intended for administration through the mouth.

Oral Gavage Route of Administration

Administration through the mouth and into the stomach, usually by means of a tube.

Oral Foam Dosage Form

A foam intended for administration through the mouth.

Oral Fludarabine Phosphate

An oral formulation of the phosphate salt of fludarabine, a synthetic purine nucleoside analogue antimetabolite with antineoplastic activity. Fudarabine is preferentially transported…